Prostate cancer and curcumin: Add spice to your life

Cancer Biology and Therapy

Volumn 7, Issue 9, 2008, Pages 1436-1440

  Aggarwal, Bharat B ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Cytokine Research Laboratory   (United States)

Author keywords

Androgen dependent; Androgen independent; Curcumin; EGFR; HER2; NFkB; Prostate cancer; PSA

Indexed keywords

ANDROGEN RECEPTOR; ANTIANDROGEN; ANTIINFLAMMATORY AGENT; BEVACIZUMAB; BIOLOGICAL MARKER; CURCUMIN; CYCLIN D1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; PROSTATE SPECIFIC ANTIGEN; PROTEIN BCL 2; STAT3 PROTEIN; ANDROGEN; ANTINEOPLASTIC AGENT;

CANCER PREVENTION; CANCER SURVIVAL; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; DOWN REGULATION; DRUG EFFICACY; DRUG INHIBITION; EMBRYO DEVELOPMENT; GENE OVEREXPRESSION; HUMAN; NONHUMAN; NOTE; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN FOLDING; SIGNAL TRANSDUCTION; CELL SURVIVAL; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; INDIA; MALE; NEOPLASM; NORTH AMERICA; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; SPICE; TUMOR CELL LINE;

ANDROGENS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CURCUMIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDIA; MALE; NEOPLASMS, HORMONE-DEPENDENT; NORTH AMERICA; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; SPICES;

EID: 58149143164     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.7.9.6659     Document Type: Note

References (57)

1. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003; 349:366-81.
2. Gronberg H. Prostate cancer epidemiology. Lancet 2003; 361:859-64.
3. Isaacs W, De Marzo A, Nelson WG. Focus on prostate cancer. Cancer Cell 2002; 2:113-6.
4. Haenszel W, Kurihara M. Studies of Japanese migrants I. Mortality from cancer and other diseases among Japanese in the United States. J Natl Cancer Inst 1968; 40:43-68.
5. Craft N, Chhor C, Tran C, et al. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res 1999; 59:5030-6.
6. Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS, Buttyan R. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 1995; 55:4438-45.
7. Shah RB, Ghosh D, Elder JT. Epidermal growth factor receptor (ErbB1) expression in prostate cancer progression: correlation with androgen independence. Prostate 2006; 66:1437-44.
8. Wang X, Jones TD, Zhang S, et al. Amplifications of EGFR gene and protein expression of EGFR, Her-2/neu, c-kit and androgen receptor in phyllodes tumor of the prostate. Mod Pathol 2007; 20:175-82.
9. Fu M, Wang C, Li Z, Sakamaki T and Pestell RG. Minireview: Cyclin D1: normal and abnormal functions. Endocrinology 2004; 145:5439-47.
10. Liu XH, Yao S, Kirschenbaum A and Levine AC. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and downregulates bcl-2 expression in LNCaP cells. Cancer Res 1998; 58:4245-9.
11. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 2003; 23:363-98.
12. Lao CD, Ruffin MTT, Normolle D, et al. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 2006; 6:10.
13. Mukhopadhyay A, Bueso-Ramos C, Chatterjee D, Pantazis P, Aggarwal BB. Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene 2001; 20:7597-609.
14. Dorai T, Gehani N, Katz A. Therapeutic potential of curcumin in human prostate cancer-I. curcumin induces apoptosis in both androgen-dependent and androgen-independent prostate cancer cells. Prostate Cancer Prostatic Dis 2000; 3:84-93.
15. Dorai T, Cao YC, Dorai B, Buttyan R, Katz AE. Therapeutic potential of curcumin in human prostate cancer III. Curcumin inhibits proliferation, induces apoptosis and inhibits angiogenesis of LNCaP prostate cancer cells in vivo. Prostate 2001; 47:293-303.
16. Dorai T, Dutcher JP, Dempster DW, Wiernik PH. Therapeutic potential of curcumin in prostate cancer - V: Interference with the osteomimetic properties of hormone refractory C4-2B prostate cancer cells. Prostate 2004; 60:1-17.
17. Khor TO, Keum YS, Lin W, et al. Combined inhibitory effects of curcumin and phenethyl isothiocyanate on the growth of human PC-3 prostate xenografts in immunodeficient mice. Cancer Res 2006; 66:613-21.
18. Chendil D, Ranga RS, Meigooni D, Sathishkumar S, Ahmed MM. Curcumin confers radiosensitizing effect in prostate cancer cell line PC-3. Oncogene 2004; 23:1599-607.
19. Nakamura K, Yasunaga Y, Segawa T, et al. Curcumin downregulates AR gene expression and activation in prostate cancer cell lines. Int J Oncol 2002; 21:825-30.
20. Zhang HN, Yu CX, Zhang PJ, et al. Curcumin downregulates homeobox gene NKX3.1 in prostate cancer cell LNCaP. Acta Pharmacol Sin 2007; 28:423-30.
21. Ohtsu H, Xiao Z, Ishida J, et al. Antitumor agents 217. Curcumin analogues as novel androgen receptor antagonists with potential as anti-prostate cancer agents. J Med Chem 2002; 45:5037-42.
22. Tillotson JKRD. Density-dependent regulation of epidermal growth factor receptor expression in DU 145 human prostate cancer cells. Prostate 1991; 19:53-61.
23. Korutla L, Cheung JY, Mendelsohn J, Kumar R. Inhibition of ligand-induced activation of epidermal growth factor receptor tyrosine phosphorylation by curcumin. Carcinogenesis 1995; 16:1741-5.
24. Edwards J, Mukherjee R, Munro AF, Wells AC, Almushatat A, Bartlett JM. HER2 and COX2 expression in human prostate cancer. Eur J Cancer 2004; 40:50-5.
25. Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 1999; 5:280-5.
26. Jung Y, Xu W, Kim H, Ha N, Neckers L. Curcumin-induced degradation of ErbB2: A role for the E3 ubiquitin ligase CHIP and the Michael reaction acceptor activity of curcumin. Biochim Biophys Acta 2007; 1773:383-90.
27. Hong RL, Spohn WH, Hung MC. Curcumin inhibits tyrosine kinase activity of p185neu and also depletes p185neu. Clin Cancer Res 1999; 5:1884-91.
28. Mukhopadhyay A, Banerjee S, Stafford LJ, Xia C, Liu M, Aggarwal BB. Curcumin-induced suppression of cell proliferation correlates with downregulation of cyclin D1 expression and CDK4-mediated retinoblastoma protein phosphorylation. Oncogene 2002; 21:8852-61.
29. Zha S, Gage WR, Sauvageot J, et al. Cyclooxygenase-2 is upregulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res 2001; 61:8617-23.
30. Aggarwal S, Ichikawa H, Takada Y, Sandur SK, Shishodia S, Aggarwal BB. Curcumin (diferuloylmethane) downregulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkappaBalpha kinase and Akt activation. Mol Pharmacol 2006; 69:195-206.
31. Chen CD, Sawyers CL. NFkappaB activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. Mol Cell Biol 2002; 22:2862-70.
32. Yang L, Zhang LY, Chen WW, et al. [Inhibition of the expression of prostate specific antigen by curcumin]. Yao Xue Xue Bao 2005; 40:800-3.
33. Hatziapostolou M, Polytarchou C, Katsoris P, Courty J, Papadimitriou E. Heparin affin regulatory peptide/pleiotrophin mediates fibroblast growth factor 2 stimulatory effects on human prostate cancer cells. J Biol Chem 2006; 281:32217-26.
34. Mohan R, Chintala SK, Jung JC, et al. Matrix metalloproteinase gelatinase B (MMP-9) coordinates and effects epithelial regeneration. J Biol Chem 2002; 277:2065-72.
35. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS and McCauley LK. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 2002; 62:1832-7.
36. Skommer J, Wlodkowic D, Pelkonen J. Gene-expression profiling during curcumin-induced apoptosis reveals downregulation of CXCR4. Exp Hematol 2007; 35:84-95.
37. Okamoto M, Lee C, Oyasu R. Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res 1997; 57:141-6.
38. Giri D, Ozen M, Ittmann M. Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol 2001; 159:2159-65.
39. Cho JW, Lee KS, Kim CW. Curcumin attenuates the expression of IL-1beta, IL-6 and TNFalpha as well as cyclin E in TNFalpha-treated HaCaT cells; NFkappaB and MAPKs as potential upstream targets. Int J Mol Med 2007; 19:469-74.
40. Bharti AC, Donato N, Aggarwal BB. Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol 2003; 171:3863-71.
41. Davies MA, Koul D, Dhesi H, et al. Regulation of Akt/PKB activity, cellular growth and apoptosis in prostate carcinoma cells by MMAC/PTEN. Cancer Res 1999; 59:2551-6.
42. Lin J, Adam RM, Santiestevan E and Freeman MR. The phosphatidylinositol 3′-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells. Cancer Res 1999; 59:2891-7.
43. Bharti AC, Takada Y, Aggarwal BB. Curcumin (diferuloylmethane) inhibits receptor activator of NFkappaB ligand-induced NFkappaB activation in osteoclast precursors and suppresses osteoclastogenesis. J Immunol 2004; 172:5940-7.
44. Rini BI, Weinberg V, Fong L, Conry S, Hershberg RM and Small EJ. Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Cancer 2006; 107:67-74.
45. Gururaj AE, Belakavadi M, Venkatesh DA, Marme D, Salimath BP. Molecular mechanisms of anti-angiogenic effect of curcumin. Biochem Biophys Res Commun 2002; 297:934-42.
46. Arbiser JL, Klauber N, Rohan R, et al. Curcumin is an in vivo inhibitor of angiogenesis. Mol Med 1998; 4:376-83.
47. Catz SD, Johnson JL. Transcriptional regulation of bcl-2 by nuclear factor kappaB and its significance in prostate cancer. Oncogene 2001; 20:7342-51.
48. Herrmann JL, Briones F Jr, Brisbay S, Logothetis CJ and McDonnell TJ. Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53. Oncogene 1998; 17:2889-99.
49. Lessard L, Begin LR, Gleave ME, Mes-Masson AM, Saad F. Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: an immunohistochemical study. Br J Cancer 2005; 93:1019-23.
50. Huang S, Pettaway CA, Uehara H, Bucana CD and Fidler IJ. Blockade of NFkappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion and metastasis. Oncogene 2001; 20:4188-97.
51. Singh S, Aggarwal BB. Activation of transcription factor NFkappaB is suppressed by curcumin (diferuloylmethane) [corrected]. J Biol Chem 1995; 270:24995-5000.
52. + cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood 2004; 103:3175-84.
53. 1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochem Pharmacol 2005; 70:700-13.
54. Aggarwal BB, Takada Y, Oommen OV. From chemoprevention to chemotherapy: common targets and common goals. Expert Opin Investig Drugs 2004; 13:1327-38.
55. Abbruzzese JL and Lippman SM. The convergence of cancer prevention and therapy in early-phase clinical drug development. Cancer Cell 2004; 6:321-6.
56. Thangapazham RL, et al. (this issue).
57. Yan C, Jamaluddin MS, Aggarwal B, Myers J, Boyd DD. Gene expression profiling identifies activating transcription factor 3 as a novel contributor to the proapoptotic effect of curcumin. Mol Cancer Ther 2005; 4:233-41.